Iqvia lab service joint venture commits $73m to US facility

By Nick Taylor

- Last updated on GMT

(Image: Getty/Darwin Brandis)
(Image: Getty/Darwin Brandis)

Related tags IQVIA Q2 Solutions Covance LabCorp North carolina

Iqvia and Quest Diagnostics' joint venture commits $73m to North Carolina expansion after securing financial incentives.

The creation of Q2​ Solutions dates back to 2015​ when Quintiles, now IQVIA, and Quest Diagnostics teamed up to create a clinical trial laboratory services business. News of the joint venture emerged shortly after Quest’s chief rival, LabCorp, closed a deal to buy one of Quintiles’ main competitors​, Covance.

By combining their assets, Quintiles and Quest created the world’s second largest central laboratory services company, Q2​. Now, Q2​ has laid the groundwork for further expansion.

Q2​ plans to invest $73m (€66m) in a new facility in Durham, North Carolina, creating 749 jobs in the process. The project will see Q2​ move its headquarters from Morrisville to the neighboring city of Durham.

With Q2​ headquartered in Morrisville and its parent company, Iqvia, based in Durham, North Carolina was a likely location for the new facility. However, in keeping with modern interstate competition for new facilities, North Carolina offered incentives to Q2​ to secure the facility.

North Carolina has signed off on two Job Development Investment Grants (JDIGs) worth $4.3m and $5.3m. The second, larger payment covers the second phase of the project, which is due to start in 2023. Both payments will be spread over 12 years.

The state’s willingness to put up the money reflects calculations that the project will add more than $1bn to the economy of North Carolina and create jobs with starting salaries well above the $69,000 average for Durham County.

North Carolina may withhold some of the payments if Q2​ fails to uphold its end of the bargain. Both payments are contingent upon Q2​ meeting incremental job creation and investment targets. Through that caveat, North Carolina thinks it can ensure the JDIG projects are a net positive for tax revenues.

The JDIG agreements also cover plans to move $3.2m into a fund designed to help rural communities invest in the infrastructure upgrades needed to attract future business.  

Q2​ framed the investment in North Carolina as supporting its efforts to meet “explosive demand for regulatory compliant genomic testing in clinical trials​” and provide translational services.

Q2​ CEO Brian O’Dwyer said, “The market for genomic testing in clinical trials has expanded rapidly over the past five years and, with the increased information provided to clinical development programs from genomic data, we are expanding our capacity and offerings in North Carolina. To complement the expansion in genomics, we are also creating a dedicated Translational Science and Innovation Laboratory​.”

Related news

Show more

Related products

show more

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Validate clinical study data with Formedix CORE

Validate clinical study data with Formedix CORE

Content provided by Formedix | 19-Jun-2023 | White Paper

In April 2023 at the CDISC Europe Interchange, we launched Formedix CORE, the first free-to-use, downloadable application encompassing the CDISC Open Rules...

Related suppliers

Follow us


View more